Efficacy and Safety of First-Line Platinum-Based Doublet Chemotherapy in Advanced Primary Pulmonary Salivary Gland Tumors (PSGTs)
Primary pulmonary salivary gland tumors (PSGT) constitute a rare subtype of non-small cell lung cancer (NSCLC). Currently, no established treatment guidelines exist for advanced PSGT. The efficacy of platinum-based chemotherapy for PSGT within the context of NSCLC remains uncertain. Therefore, we retrospectively collected 37 PSGT patients who underwent first-line platinum-based chemotherapy from 2010 to 2023. Survival analysis, employing the Kaplan-Meier method, and group comparisons via the log rank test were conducted. Our results show that first-line platinum-based chemotherapy demonstrates favorable efficacy and manageable safety in advanced PSGT, with the combination of Paclitaxel + Platinum emerging as a preferred option.
Authors
- Zheng Shi (ORCID: https://orcid.org/0000-0001-8282-3913)
- Jingwen Wei (ORCID: https://orcid.org/0000-0001-9185-3604)
- Manyi Xu (ORCID: https://orcid.org/0000-0002-6937-3652)
- Keda Shao (ORCID: https://orcid.org/0009-0005-5414-6309)
- Wei Sun (ORCID: https://orcid.org/0000-0003-1416-3313)
- Zhengbo Song
- Chunwei Xu (ORCID: https://orcid.org/0000-0001-6898-4307)
- Xiaohong Zeng
Institutions
- Zhejiang Chinese Medical University (CN)
- Chinese Academy of Sciences (CN)
- Wenzhou Medical University (CN)
- Zhejiang Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Investigation
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1080/07357907.2024.2399046
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation
- Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
- Medical Scientific Research Foundation of Zhejiang Province, China